You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Harvard Business School

Last Updated: October 25, 2020

DrugPatentWatch Database Preview

Patent: 10,072,301

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,072,301
Title:Means and methods for molecular classification of breast cancer
Abstract: The invention relates to a method of typing a sample from a breast cancer patient. More specifically, the invention relates to a method for classification of breast cancer according to the presence or absence of Estrogen Receptor (ER), Progesterone Receptor (PR) and Human Epidermal growth factor Receptor 2 (ERBB2; HER2). More specifically, the invention provides methods and means to classify breast cancer as ER positive, triple negative (ER.sup.-, PR.sup.- and HER2.sup.-) and HER2+.
Inventor(s): Krijgsman; Oscar (Almere, NL), Roepman; Paul (Bilthoven, NL), Glas; Annuska Maria (Assendelft, NL)
Assignee: Agendia N.V. (Amsterdam, NL)
Application Number:14/925,838
Patent Claims:see list of patent claims

Details for Patent 10,072,301

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech Inc HERCEPTIN HYLECTA trastuzumab; hyaluronidase-oysk INJECTABLE;SUBCUTANEOUS 761106 001 2019-02-28   Start Trial Agendia N.V. (Amsterdam, NL) 2031-07-13 RX search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Start Trial Agendia N.V. (Amsterdam, NL) 2031-07-13 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.